secwatch / observer
8-K filed May 5, 2026, 7:59 PM ET ticker QURE CIK 0001590560
earnings confidence high sentiment negative materiality 0.70

uniQure Q1 net loss $53.5M ($0.85/share); AMT-130 UK MAA on track for Q3

uniQure N.V.

2026-Q1 EPS reported -$0.85 revenue$3,562,000
item 2.02item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001104659-26-055242
form_type
8-K
ticker
QURE
cik
0001590560
company_name
uniQure N.V.
filed_at
2026-05-05T23:59:59+00:00
discovered_at
2026-05-14T18:02:32.532048+00:00
generated_at
2026-05-14T23:22:21.035844+00:00
sec_items
["2.02", "9.01"]
event_type
earnings
sentiment
negative
materiality_score
0.7
calibrated_materiality_score
0.7
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001104659-26-055242
json_url
https://secwatch.observer/filing/0001104659-26-055242.json
markdown_url
https://secwatch.observer/filing/0001104659-26-055242.md
text_url
https://secwatch.observer/filing/0001104659-26-055242.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/0001104659-26-055242-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1590560/000110465926055242/qure-20260505x8k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

ff12cb5a3472abb9886e5bad94d25b96da6c5cbb

uniQure N.V. reported financial results for first quarter of 2026.

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.

SEC 8-K Item 2.02 confidence 0.95 SEC evidence

ff12cb5a3472abb9886e5bad94d25b96da6c5cbb

uniQure N.V. reported financial results for first quarter of 2026.

Strong balance sheet with $586.6 million in cash, cash equivalents and current investment securities as of March 31, 2026 and runway into the second half of 2029

SEC 8-K Item 2.02 confidence 0.95 SEC evidence

Comparable filings

GTLB

GitLab Q1 revenue $264M (+23% YoY); plans 14% workforce cut, $30-35M charges

Gitlab Inc. June 2, 2026, 4:17 PM ET earnings Items 2.02, 2.05, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.

Comparable filing

in such filing. --- EX-99.1 (EX-99.1) --- GitLab Reports First Quarter Fiscal Year 2027 Financial Results First Quarter Fiscal Year 2027 Highlights: • Total revenue of $264.2 million, up 23% year-over-year • GAAP operating margin of (6)%; non-GAAP operating margin of 14% • Operating cash flow of $149.2 million and non-GAAP adjusted free cash flow of $146.7

Filing page SEC filing

PETS

PetMed Q4 sales fall 15.6% to $42.8M; FY net loss widens to $57.3M on goodwill impairment

PETMED EXPRESS INC June 2, 2026, 4:15 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.

Comparable filing

Net sales of $179.0 million compared to $227.0 million in the prior year, a decrease of 21.1%, primarily driven by a decline in prescription medication sales. • Net loss of $57.3 million, or $(2.74) per diluted share, compared to a net loss of $6.3 million, or $(0.30) per diluted share in the prior year.

Filing page SEC filing

SPWH

Sportsman's Warehouse Q1 net sales up 2.8% to $256.1M; same-store sales +2.1%; net loss $21.8M

SPORTSMAN'S WAREHOUSE HOLDINGS, INC. June 2, 2026, 4:10 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.

Comparable filing

and generating positive free cash flow to further strengthen our balance sheet through debt reduction.” For the thirteen weeks ended May 2, 2026: • Net sales increased 2.8% to $256.1 million, compared to $249.1 million in the first quarter of fiscal year 2025. Performance was driven primarily by a 7.4% gain in Hunting and Shooting Sports, led by firearms, ammunition,

Filing page SEC filing

ULTA

Ulta Q1 net sales +11.1% to $3.16B, comps +5.3%; FY EPS guidance raised to $28.36-$28.80

Ulta Beauty, Inc. June 2, 2026, 4:06 PM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.

Comparable filing

compared to the same period ended May 3, 2025 : ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 13 Weeks Ended ​ ​ May 2, ​ May 3, (Dollars in millions, except per share data) ​ 2026 ​ 2025 Net sales ​ $ 3,163.9 ​ $ 2,848.4 Comparable sales ​ ​ 5.3% ​ ​ 2.9% Gross profit (as a percentage of net sales) ​ ​ 40.1% ​ ​ 39.1% Selling, general and administrative expenses ​ $ 814.7 ​ $ 710.6

Filing page SEC filing

YEXT

Yext Q1 FY27: Adj EBITDA margin 25%, ARR $440.8M; boosts buyback by $100M

Yext, Inc. June 2, 2026, 4:05 PM ET earnings Items 2.02, 8.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.

Comparable filing

Exchange Act, except as expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Yext Announces First Quarter Fiscal 2027 Results – Revenue of $107.9 million – Net Income Per Share, basic, of $0.02 or non-GAAP Net Income Per Share of $0.15 – Adjusted EBITDA of $26.9 million, resulting in an Adjusted EBITDA margin of 25% – ARR of

Filing page SEC filing

IVF

INVO Fertility FY2025 revenue $6.84M (+5% YoY); net loss improves to $(5.3)M

INVO Fertility, Inc. June 2, 2026, 8:40 AM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.

Comparable filing

and technologies, today announced fiscal year 2025 financial results. FY2025 Financial Highlights (all metrics compared to FY2024 unless otherwise noted) ● Revenue was $6,841,250, an increase of 5% compared to $6,532,000. ● Consolidated clinic revenue increased 4% to $6,721,057, compared to $6,450,431. ● Revenue from all clinics was $8,021,929, including

Filing page SEC filing

POLA

Polar Power Q1 net loss narrows 86% to $178K; gross margin expands to 65.7%

Polar Power, Inc. June 2, 2026, 8:30 AM ET earnings Items 2.02, 7.01, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.

Comparable filing

Q1 2026 Q1 2025 Y/Y +/(-) Change Net sales $ 1,728 $ 1,723 — Gross profit $ 1,135 $ 320 255 % Gross margin 65.7 % 18.6 % 47.1 pts Total operating expenses $ 1,111 $ 1,421 22 % Income (loss) from operations $ 24 $ (1,101 ) 102 % Net loss $ (178 ) $ (1,265 ) 86 % Net loss per share $ (0.05 ) $ (0.50 ) 90 %

Filing page SEC filing

CTRN

Citi Trends Q1 sales up 14.4% to $230.9M; adjusted EBITDA doubles to $13.9M

Citi Trends Inc June 2, 2026, 6:58 AM ET earnings Items 2.02, 9.01

same fact type: earnings_release same SEC item: 2.02, 9.01 same event type: earnings similar materiality

This filing

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2026 and highlighted recent progress across its business.

Comparable filing

(EXHIBIT 99.1) --- EX-99.1 2 tm2616574d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CITITRENDS ANNOUNCES FIRST QUARTER FISCAL 2026 RESULTS Q1 2026 total sales increased 14.4% to $230.9 million Comparable store sales growth of 13.9%; Two-year stack of 23.8% Q1 2026 Net Income of $7.8 million; Q1 2026 adjusted EBITDA* of $13.9 million, more than double Q1 2025 results

Filing page SEC filing

Source: SEC EDGAR
accession 0001104659-26-055242
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.